| Project/Area Number |
22890016
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,146,000 (Direct Cost: ¥2,420,000、Indirect Cost: ¥726,000)
Fiscal Year 2011: ¥1,508,000 (Direct Cost: ¥1,160,000、Indirect Cost: ¥348,000)
Fiscal Year 2010: ¥1,638,000 (Direct Cost: ¥1,260,000、Indirect Cost: ¥378,000)
|
|---|
| Keywords | 糖尿病性腎症 / 凝固第三因子 / マウス / 血液凝固 / 一酸化窒素合成酵素 / 内皮型一酸化窒素合成酵素 / 凝固第3因子 / アキタマウス / マクロファージ |
|---|
| Research Abstract |
Diabetic nephropathy (DN)is the leading cause of end stage renal disease, and the number of patients with DN has been increasing rapidly. Human variants of the endothelial nitric oxide synthase gene (eNOS, NOS3)that produce reduced amounts of nitric oxide (NO)are positively associated with DN, although proof of causation is lacking. Here we have demonstrated that eNOS-/-mice with diabetes develop severe nephropathy. However, complete absence of eNOS has not been reported in humans, although reduced levels are not infrequent. Accordingly, heterozygous eNOS+/-mice have been made diabetic, and they demonstrated that the decrease in eNOS/NO comparable to that of NOS3 polymorphisms is sufficient to cause exacerbation of DN. Increased expression of tissue factor, initiator of coagulation, likely plays a significant role in the DN of the eNOS-/-diabetic mice. Strategies to ameliorate hypercoagulability could be useful for treatment of DN.
|
